We are committed to creating innovative and safe solutions for all patient groups, particularly for vulnerable populations such as pediatric and neonatal patients. One of our key innovations was the development of a product free of Polyethylene glycol (PEG), a compound not considered safe for use in children or neonates.

Polyethylene glycol, commonly used as a stabilizer or excipient in pharmaceutical formulations, can pose potential risks for pediatric patients, especially infants. Recognizing the need for a safer alternative, we reformulated our product eliminating PEG, ensuring that it met the highest safety standards for young patients.

This modification significantly enhanced the product’s suitability for pediatric and neonatal use, allowing healthcare providers to administer the treatment with confidence. By eliminating PEG, we not only ensured the safety of our formulation but also provided an effective and reliable treatment option for younger patients.